Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCS vs GC in unresectable biliary tract cancer
NCT02182778Phase 3Completed
- Sponsor
- Kansai Hepatobiliary Oncology Group
- Start
- Jul 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur in biliary tract cancer (BTC), sponsored by Kansai Hepatobiliary Oncology Group. Started Jul 2014; status: completed.
02
Drugs
tegafur
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02182778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182778.